Selected Publications
Stereotactic ablative radiotherapy with or without immunotherapy for early-stage or isolated lung parenchymal recurrent node-negative non-small-cell lung cancer: an open-label, randomised, phase 2 trial. Chang JY, Lin SH, Dong W, Liao Z, Gandhi SJ, Gay CM, Zhang J, Chun SG, Elamin YY, Fossella FV, Blumenschein G, Cascone T, Le X, Pozadzides JV, Tsao A, Verma V, Welsh JW, Chen AB, Altan M, Mehran RJ, Vaporciyan AA, Swisher SG, Balter PA, Fujimoto J, Wistuba II, Feng L, Lee JJ, Heymach JV. Stereotactic ablative radiotherapy with or without immunotherapy for early-stage or isolated lung parenchymal recurrent node-negative non-small-cell lung cancer: an open-label, randomised, phase 2 trial. Lancet. e-Pub 7/2023. PMID: 37478883.
MCT4-dependent lactate secretion suppresses antitumor immunity in LKB1-deficient lung adenocarcinoma. Qian Y, Galan-Cobo A, Guijarro I, Dang M, Molkentine D, Poteete A, Zhang F, Wang Q, Wang J, Parra E, Panda A, Fang J, Skoulidis F, Wistuba II, Verma S, Merghoub T, Wolchok JD, Wong KK, DeBerardinis RJ, Minna JD, Vokes NI, Meador CB, Gainor JF, Wang L, Reuben A, Heymach JV. Cancer Cell 41(7):1363-1380.e7, 7/2023. e-Pub 6/2023. PMID: 37327788.
IL-6 mediates suppression of T and NK cells function in EMT-associated TKI-resistant EGFR mutant NSCLC. Patel SA, Nilsson MB, Yang Y, Le X, Tran HT, Elamin YY, Yu X, Zhang F, Poteete A, Ren X, Shen L, Wang J, Moghaddam SJ, Cascone T, Curran M, Gibbons DL, Heymach JV. Clin Cancer Res 29(7):1292-1304, 4/2023. e-Pub 1/2023. PMCID: PMC10290888.
A Phase I, Open-Label, Dose Confirmation, Escalation, and Expansion Trial of BI 1810631 as Monotherapy in Patients With Advanced or Metastatic Solid Tumors With HER2 Aberrations. Heymach J, Opdam F, Barve M, Gibson N, Sadrolhefazi B, Serra J, Yamamoto N. Clin Lung Cancer 24(2):e65-e68, 3/2023. e-Pub 11/2022. PMID: 36528522.
Molecular Mechanisms and Future Implications of VEGF/VEGFR in Cancer Therapy. Patel SA, Nilsson MB, Le X, Cascone T, Jain RK, Heymach JV. Clin Cancer Res 29(1):30-39, 1/2023. e-Pub 8/2022. PMID: 35969170.
Design and Rationale for a Phase III, Double-Blind, Placebo-Controlled Study of Neoadjuvant Durvalumab+Chemotherapy Followed by Adjuvant Durvalumab for the Treatment of Patients With Resectable Stages II and III non-small-cell Lung Cancer: The AEGEAN Trial. Heymach JV, Mitsudomi T,
Harpole D, Aperghis M, Jones S, Mann H, Fouad TM, Reck M. Clin Lung Cancer 23(3):e247-e251, 5/2022. e-Pub 10/2021. PMID: 34819266.
Poziotinib for Patients With HER2 Exon 20 Mutant Non-Small-Cell Lung Cancer: Results From a Phase II Trial. Elamin YY, Robichaux JP, Carter BW, Altan M, Gibbons DL, Fossella FV, Lam VK, Patel AB, Negrao MV, Le X, Mott FE, Zhang J, Feng L, Blumenschein G, Tsao AS, Heymach JV. J Clin Oncol 40(7):JCO2101113, 3/2022. e-Pub 9/2021. PMCID: PMC8887948.
Enhanced Vulnerability of LKB1-Deficient NSCLC to Disruption of ATP Pools and Redox Homeostasis by 8-Cl-Ado. Galan-Cobo A, Stellrecht CM, Yilmaz E, Yang C, Qian Y, Qu X, Akhter I, Ayres ML, Fan Y, Tong P, Diao L, Ding J, Giri U, Gudikote J, Nilsson M, Wierda WG, Wang J, Skoulidis F, Minna JD,
Gandhi V, Heymach JV. Mol Cancer Res 20(2):280-292, 2/2022. e-Pub 10/2021. PMCID: PMC8816854.
Landscape and Clonal Dominance of Co-occurring Genomic Alterations in Non-Small-Cell Lung Cancer Harboring MET Exon 14 Skipping. Le X,
Hong L, Hensel C, Chen R, Kemp H, Coleman N, Ciunci CA, Liu SV, Negrao MV, Yen J, Xia X, Scheuenpflug J, Stroh C, Juraeva D, Tsao A, Hong D, Raymond V, Paik P, Zhang J, Heymach JV. JCO Precis Oncol 5, 2021. e-Pub 12/2021. PMCID: PMC8694524.
Estrogen Promotes Resistance to Bevacizumab in Murine Models of NSCLC. Patel SA, Herynk MH, Cascone T, Saigal B, Nilsson MB, Tran H, Ramachandran S, Diao L, Wang J, Le X, Minna J, Wistuba II, Heymach JV. J Thorac Oncol 16(12):2051-2064, 12/2021. e-Pub 7/2021. PMID: 34311109.
Structure-based classification predicts drug response in EGFR-mutant NSCLC. Robichaux JP, Le X, Vijayan RSK, Hicks JK, Heeke S, Elamin YY, Lin HY,
Udagawa H, Skoulidis F, Tran H, Varghese S, He J, Zhang F, Nilsson MB, Hu L, Poteete A, Rinsurongkawong W, Zhang X, Ren C, Liu X, Hong L, Zhang J, Diao L, Madison R, Schrock AB, Saam J, Raymond V, Fang B, Wang J, Ha MJ, Cross JB, Gray JE, Heymach JV. Nature. 2021 Sep;597(7878):732-737. doi 10.1038/s41586-021-03898-1. Epub 2021 Sep 15. PMID: 34526717 PMC8481125.
Inhibition of nonsense-mediated decay rescues p53β/γ isoform expression and activates the p53 pathway in MDM2-overexpressing and select p53-mutant cancers. Gudikote JP, Cascone T, Poteete A, Sitthideatphaiboon P, Wu Q, Morikawa N, Zhang F, Peng S, Tong P, Li L, Shen L, Nilsson M, Jones P, Sulman EP, Wang J, Bourdon JC, Johnson FM, Heymach JV. J Biol Chem. 2021 Nov;297(5):101163. doi: 10.1016/j.jbc.2021.101163. Epub 2021 Sep 3. PMID: 34481841; PMCID: PMC8569473.
Estrogen Promotes Resistance to Bevacizumab in Murine Models of NSCLC. Patel SA, Herynk MH, Cascone T, Saigal B, Nilsson MB, Tran H, Ramachandran S, Diao L, Wang J, Le X, Minna J, Wistuba II, Heymach JV. J Thorac Oncol. 2021 Dec;16(12):2051-2064. doi: 10.1016/j.jtho.2021.07.007. Epub 2021 Jul 24. PMID: 34311109.
Characterization of the Immune Landscape of EGFR-Mutant NSCLC Identifies CD73/Adenosine Pathway as a Potential Therapeutic Target. Le X, Negrao MV, Reuben A, Federico L, Diao L, McGrail D, Nilsson M, Robichaux J, Munoz IG, Patel S, Elamin Y, Fan YH, Lee WC, Parra E, Solis Soto LM, Chen R, Li J, Karpinets T, Khairullah R, Kadara H, Behrens C, Sepesi B, Wang R, Zhu M, Wang L, Vaporciyan A, Roth J, Swisher S, Haymaker C, Zhang J, Wang J, Wong KK, Byers LA, Bernatchez C, Zhang J, Wistuba II, Gibbons DL, Akbay EA, Heymach JV. J Thorac Oncol. 2021 Apr;16(4):583-600. doi: 10.1016/j.jtho.2020.12.010. Epub 2020 Dec 31. PMID: 33388477.
STK11/LKB1 Mutations in NSCLC Are Associated with KEAP1/NRF2-Dependent Radiotherapy Resistance Targetable by Glutaminase Inhibition. Sitthideatphaiboon P, Galan-Cobo A, Negrao MV, Qu X, Poteete A, Zhang F, Liu DD, Lewis WE, Kemp HN, Lewis J, Rinsurongkawong W, Giri U, Lee JJ, Zhang J, Roth JA, Swisher S, Heymach JV. Clin Cancer Res. 2021 Mar 15;27(6):1720-1733. doi: 10.1158/1078-0432.CCR-20-2859. Epub 2020 Dec 15. PMID: 33323404; PMCID: PMC8138942.
Altered Regulation of HIF-1α in Naive- and Drug-Resistant EGFR-Mutant NSCLC: Implications for a Vascular Endothelial Growth Factor-Dependent Phenotype. Nilsson MB, Robichaux J, Herynk MH, Cascone T, Le X, Elamin Y, Patel S, Zhang F, Xu L, Hu L, Diao L, Shen L, He J, Yu X, Nikolinakos P, Saintigny P, Fang B, Girard L, Wang J, Minna JD, Wistuba II, Heymach JV. J Thorac Oncol. 2021 Mar;16(3):439-451. doi: 10.1016/j.jtho.2020.11.022. Epub 2020 Dec 9. PMID: 33309987; PMCID: PMC8207565.
A YAP/FOXM1 axis mediates EMT-associated EGFR inhibitor resistance and increased expression of spindle assembly checkpoint components. Nilsson MB, Sun H, Robichaux J, Pfeifer M, McDermott U, Travers J, Diao L, Xi Y, Tong P, Shen L, Hofstad M, Kawakami M, Le X, Liu X, Fan Y, Poteete A, Hu L, Negrao MV, Tran H, Dmitrovsky E, Peng D, Gibbons DL, Wang J, Heymach JV. Sci Transl Med. 2020 Sep 2;12(559):eaaz4589. doi: 10.1126/scitranslmed.aaz4589. PMID: 32878980; PMCID: PMC8269000.
Pan-Cancer Landscape and Analysis of ERBB2 Mutations Identifies Poziotinib as a Clinically Active Inhibitor and Enhancer of T-DM1 Activity. Robichaux JP, Elamin YY, Vijayan RSK, NilssonMB, Hu L, He J, Zhang F, Pisegna M, Poteete A, Sun H, Li S, Chen T, Han H, Negrao MV, Ahnert JR, Diao L, Wang J, Le X, Meric-Bernstam F, Routbort M, RoeckB, Yang Z, Raymond VM, Lanman RB, Frampton GM, Miller VA, Schrock AB, Albacker LA, Wong KK, Cross JB, Heymach JV. Cancer Cell. 2020 Mar 16;37(3):420. doi: 10.1016/j.ccell.2020.03.003. Erratum for: Cancer Cell. 2019 Oct 14;36(4):444-457.e7. PMID: 32183953; PMCID: PMC7241090.
LKB1 and KEAP1/NRF2 Pathways Cooperatively Promote Metabolic Reprogramming with Enhanced Glutamine Dependence in KRAS-Mutant Lung Adenocarcinoma Galan-Cobo A, Sitthideatphaiboon P, Qu X, Poteete A, Pisegna MA, Tong P,Chen PH, Boroughs LK, Rodriguez MLM, Zhang W, Parlati F, Wang J, Gandhi V, Skoulidis F, DeBerardinis RJ, Minna JD, Heymach JV. Cancer Res. 2019 Jul1;79(13):3251-3267. doi: 10.1158/0008-5472.CAN-18-3527. Epub 2019 Apr 30. PMID: 31040157; PMCID: PMC6606351
Landscape of EGFR-Dependent and -Independent Resistance Mechanisms to Osimertinib and Continuation Therapy Beyond Progression in EGFR-Mutant NSCLC. Le X, Puri S, Negrao MV, Nilsson MB, Robichaux J, Boyle T, Hicks JK, Lovinger KL, Roarty E, Rinsurongkawong W, Tang M, Sun H, Elamin Y, Lacerda LC, Lewis J, Roth JA, Swisher SG, Lee JJ, William WN Jr, Glisson BS, Zhang J, Papadimitrakopoulou VA, Gray JE, Heymach JV. Clin Cancer Res. 2018 Dec 15;24(24):6195-6203. doi: 10.1158/1078-0432.CCR-18-1542. Epub 2018 Sep 18. PMID: 30228210
STK11/LKB1 Mutations and PD-1 Inhibitor Resistance in KRAS-Mutant Lung Adenocarcinoma. Skoulidis F, Goldberg ME, Greenawalt DM, Hellmann MD, Awad MM, Gainor JF, Schrock AB, Hartmaier RJ, Trabucco SE, Gay L, Ali SM, Elvin JA, Singal G, Ross JS, Fabrizio D, Szabo PM, Chang H, Sasson A, Srinivasan S, Kirov S, Szustakowski J, Vitazka P, Edwards R, Bufill JA, Sharma N, Ou SI, Peled N, Spigel DR, Rizvi H, Aguilar EJ, Carter BW, Erasmus J, Halpenny DF, Plodkowski AJ, Long NM, Nishino M, Denning WL, Galan-Cobo A, Hamdi H, Hirz T, Tong P, Wang J, Rodriguez-Canales J, Villalobos PA, Parra ER, Kalhor N, Sholl LM, Sauter JL, Jungbluth AA, Mino-Kenudson M, Azimi R, Elamin YY, Zhang J, Leonardi GC, Jiang F, Wong KK, Lee JJ, Papadimitrakopoulou VA, Wistuba II, Miller VA, Frampton GM, Wolchok JD, Shaw AT, Jänne PA, Stephens PJ, Rudin CM, Geese WJ, Albacker LA, Heymach JV. Cancer Discov. 2018 Jul;8(7):822-835. doi: 10.1158/2159-8290.CD-18-0099. Epub 2018 May 17.
Mechanisms and clinical activity of an EGFR and HER2 exon 20-selective kinase inhibitor in non-small cell lung cancer. Robichaux JP, Elamin YY, Tan Z, Carter BW, Zhang S, Liu S, Li S, Chen T, Poteete A, Estrada-Bernal A, Le AT, Truini A, Nilsson MB, Sun H, Roarty E, Goldberg SB, Brahmer JR, Altan M, Lu C, Papadimitrakopoulou V, Politi K, Doebele RC, Wong KK, Heymach JV. Nat Med. 2018 May;24(5):638-646. doi: 10.1038/s41591-018-0007-9. Epub 2018 Apr 23.
Antitumor activity of CD56-chimeric antigen receptor T cells in neuroblastoma and SCLC models. Crossland DL, Denning WL, Ang S, Olivares S, Mi T, Switzer K, Singh H, Huls H, Gold KS, Glisson BS, Cooper LJ, Heymach JV. Oncogene. 2018 Jul;37(27):3686-3697. doi: 10.1038/s41388-018-0187-2. Epub 2018 Apr 6.
Integrative proteomic and transcriptomic analysis provides evidence for TrkB (NTRK2) as a therapeutic target in combination with tyrosine kinase inhibitors for non-small cell lung cancer. Gomez DR, Byers LA, Nilsson M, Diao L, Wang J, Li L, Tong P, Hofstad M, Saigal B, Wistuba I, Kalhor N, Swisher S, Fan Y, Hong WK, Suraokar M, Behrens C, Moran C, Heymach JV. Oncotarget. 2018 Jan 30;9(18):14268-14284. doi: 10.18632/oncotarget.24361. eCollection 2018 Mar 6.
Stress hormones promote EGFR inhibitor resistance in NSCLC: Implications for combinations with β-blockers. Nilsson MB, Sun H, Diao L, Tong P, Liu D, Li L, Fan Y, Poteete A, Lim SO, Howells K, Haddad V, Gomez D, Tran H, Pena GA, Sequist LV, Yang JC, Wang J, Kim ES, Herbst R, Lee JJ, Hong WK, Wistuba I, Hung MC, Sood AK, Heymach JV. Sci Transl Med. 2017 Nov 8;9(415). pii: eaao4307. doi: 10.1126/scitranslmed.aao4307.